Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Carisma Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARIS--(BUSINESS WIRE)--REGULATORY NEWS: MARIE CHEVAL, CHAIR AND CHIEF EXECUTIVE OFFICER OF CARMILA (PARIS:CARM), COMMENTED: CARMILA'S ACCELERATED GROWTH IN THE FIRST HALF OF 2025 REFLECTS THE SCALING UP OF ITS PLATFORM AND THE SUCCESSFUL INTEGRATION OF GALIMMO. FURTHERMORE, THE GROUP'S LEASING MOMENTUM CONFIRMS THE APPEAL OF CARMILA'S SHOPPING CENTRES. THE SUCCESS OF OUR TARGETED STRATEGY FOCUSED ON ASSET TRANSFORMATION AND CAPITAL OPTIMISATION SUPPORTS SUSTAINABLE GROWTH. RECURRING EARNINGS.

CARMILA - FIRST-HALF 2025 RESULTS: ACCELERATION IN GROWTH AND RECURRING EARNINGS OUTLOOK REVISED UPWARDS

PHILADELPHIA AND MALVERN, PA., JUNE 23, 2025 (GLOBE NEWSWIRE) -- CARISMA THERAPEUTICS INC. (NASDAQ: CARM) (CARISMA) AND ORTHOCELLIX, INC. (ORTHOCELLIX), A WHOLLY-OWNED SUBSIDIARY OF OCUGEN, INC. (NASDAQ: OCGN) (OCUGEN), A CLINICAL-STAGE COMPANY DEVELOPING REGENERATIVE CELL THERAPIES FOR ORTHOPEDIC DISEASES, TODAY JOINTLY ANNOUNCED THAT THEY HAVE ENTERED INTO A DEFINITIVE MERGER AGREEMENT TO COMBINE THE COMPANIES IN AN ALL-STOCK TRANSACTION. THE COMBINED COMPANY WILL FOCUS ON THE DEVELOPMENT OF ORTHOCELLIX'S NEOCART TECHNOLOGY FOR THE TREATMENT OF KNEE ARTICULAR CARTILAGE DEFECTS AND PLANS TO INITIATE A U.S. FOOD AND DRUG ADMINISTRATION (FDA)-ENDORSED PHASE 3 CLINICAL TRIAL FOR NEOCART.

CARISMA THERAPEUTICS AND ORTHOCELLIX ENTER INTO DEFINITIVE MERGER AGREEMENT TO CREATE COMPANY FOCUSED ON REGENERATIVE CELL THERAPIES FOR ORTHOPEDIC DISEASES

COMPANY TO EXPLORE STRATEGIC ALTERNATIVES TO ADVANCE LIVER FIBROSIS AND ONCOLOGY ASSETS AND REDUCE OPERATIONAL CASH BURN PHILADELPHIA , MARCH 31, 2025 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC. (NASDAQ: CARM) ("CARISMA" OR THE "COMPANY") TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REVISED OPERATING PLAN FOCUSED ON EVALUATING STRATEGIC ALTERNATIVES WHILE REDUCING OPERATIONAL CASH BURN. THE COMPANY'S GOAL IS TO MAXIMIZE THE VALUE OF ITS ASSETS, INCLUDING ITS LIVER FIBROSIS AND ONCOLOGY DEVELOPMENT PROGRAMS, ITS MACROPHAGE AND MONOCYTE ENGINEERING PLATFORM AND THE CAR-M PLATFORM AND TO REALIZE VALUE FROM THE POTENTIAL FUTURE MILESTONE AND ROYALTY PAYMENTS UNDER CARISMA'S AGREEMENT WITH MODERNA.

CARISMA THERAPEUTICS PROVIDES CORPORATE UPDATES

PHILADELPHIA , FEB. 19, 2025 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC.(NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A LEADER IN MACROPHAGE-FOCUSED THERAPEUTICS, TODAY ANNOUNCED THAT MICHAEL KLICHINSKY, PHARMD, PHD, CO-FOUNDER AND CHIEF SCIENTIFIC OFFICER, WILL PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL CELL THERAPY VIRTUAL CONFERENCE ON TUESDAY, FEBRUARY 25 AT 10:30 AM ET.

CARISMA THERAPEUTICS TO PARTICIPATE IN H.C. WAINWRIGHT 3RD ANNUAL CELL THERAPY VIRTUAL CONFERENCE

PHILADELPHIA , FEB. 5, 2025 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC. (NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A LEADER IN MACROPHAGE-FOCUSED THERAPEUTICS, TODAY ANNOUNCED THAT STEVEN KELLY, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE ON TUESDAY, FEBRUARY 11 AT 4:40 PM ET. AN AUDIO WEBCAST OF THE EVENT WILL BE AVAILABLE ON THE COMPANY'SINVESTOR EVENTSSECTION OF THE INVESTOR RELATIONS WEBPAGE AND WILL BE ARCHIVED FOR A LIMITED TIME FOLLOWING THE EVENT.

CARISMA THERAPEUTICS TO PARTICIPATE IN OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

RESOURCES REALIGNED TO FOCUS PRIMARILY ONIN VIVO MACROPHAGE ENGINEERING PLATFORM FOR FIBROSIS, ONCOLOGY AND AUTOIMMUNE DISEASE THERAPIES DEVELOPMENT OF CT-0525 TO BE DISCONTINUED; WORKFORCE REDUCED BY 34% PHILADELPHIA , DEC. 9, 2024 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC. (NASDAQ: CARM ) ("CARISMA" OR THE "COMPANY"), A LEADER IN MACROPHAGE-FOCUSED THERAPEUTICS, TODAY ANNOUNCED A STRATEGIC REPRIORITIZATION OF ITS PIPELINE, CESSATION OF DEVELOPMENT OF CT-0525, AND A REDUCTION IN THE WORKFORCE BY 34%. THESE MEASURES WILL ENABLE CARISMA TO FOCUS ITS RESOURCES ON ADVANCING ITS IN VIVO MACROPHAGE ENGINEERING PLATFORM FOR THE DEVELOPMENT OF FIBROSIS, ONCOLOGY AND AUTOIMMUNE DISEASE THERAPIES.

CARISMA THERAPEUTICS ANNOUNCES STRATEGIC RESTRUCTURING TO RE-PRIORITIZE PIPELINE

PHILADELPHIA , NOV. 27, 2024 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC.(NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES, TODAY ANNOUNCED THAT STEVEN KELLY, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 7TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE ON THURSDAY, DECEMBER 5 TH AT 9:35 AM ET. AN AUDIO WEBCAST OF THE EVENT WILL BE AVAILABLE ON THE COMPANY'SINVESTOR EVENTSSECTION OF THE INVESTOR RELATIONS WEBPAGE AND WILL BE ARCHIVED FOR A LIMITED TIME FOLLOWING THE EVENT.

CARISMA THERAPEUTICS TO PARTICIPATE IN THE 7TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

NEW PRECLINICAL RESULTS SUPPORT THE ANTI-FIBROTIC POTENTIAL OF ENGINEERED MACROPHAGES IN MULTIPLE FIBROSIS MODELS ENGINEERED TIM4-EXPRESSING MACROPHAGES CORRECT DEFECTIVEEFFEROCYTOSIS IN MASH, DEMONSTRATING POTENT ANTI-FIBROTIC ACTIVITY PHILADELPHIA , NOV. 17, 2024 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC.(NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES, TODAY PRESENTED PROMISING PRECLINICAL DATA ON ENGINEERED MACROPHAGES FOR TREATING LIVER FIBROSIS AT THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) THE LIVER MEETING 2024. THESE RESULTS UNDERSCORE THE PRE-CLINICAL EFFICACY OF CARISMA'S ENGINEERED MACROPHAGES IN MULTIPLE LIVER FIBROSIS MODELS AND OFFER A NOVEL, OFF-THE-SHELF POTENTIAL TREATMENT OPTION FOR PATIENTS WITH FIBROTIC LIVER DISEASE INCLUDING ADVANCED METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH).

CARISMA THERAPEUTICS PRESENTS PROMISING NEW PRECLINICAL DATA ON ENGINEERED MACROPHAGES FOR THE TREATMENT OF LIVER FIBROSIS AT AASLD THE LIVER MEETING 2024

NEW FINDINGS SHOWCASE THE POTENTIAL OF IN VIVO CAR-M TECHNOLOGY AS AN EFFECTIVE, OFF-THE-SHELF TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) PHILADELPHIA , NOV. 8, 2024 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC.(NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES, TODAY ANNOUNCED POSITIVE PRE-CLINICAL DATA ON ITS ANTI-GPC3 IN VIVO CHIMERIC ANTIGEN RECEPTOR MACROPHAGE AND MONOCYTE (TOGETHER, "CAR-M") THERAPY FOR HEPATOCELLULAR CARCINOMA ("HCC"), DEVELOPED IN COLLABORATION WITH MODERNA, INC. (NASDAQ: MRNA). THE DATA DEMONSTRATED THAT THE DEVELOPMENT CANDIDATE CAN SUCCESSFULLY CREATE CAR-M DIRECTLY IN VIVO, REPROGRAMMING ENDOGENOUS MYELOID CELLS TO TARGET AND DESTROY GLYPICAN-3 ("GPC3"), EXPRESSING CANCER CELLS.

CARISMA UNVEILS PROMISING PRE-CLINICAL DATA ON ANTI-GPC3 IN VIVO CAR-M THERAPY FOR HEPATOCELLULAR CARCINOMA

INITIAL RESULTS FROM THE PHASE 1 STUDY OF CT-0525, LEAD PRODUCT CANDIDATE, EXPECTED IN THE FIRST QUARTER OF 2025 NOMINATION OF A DEVELOPMENT CANDIDATE FOR LIVER FIBROSIS PROGRAM EXPECTED IN THE FIRST QUARTER OF 2025 NEW PRECLINICAL EFFICACY DATA FROM THE ANTI-GPC3 IN VIVO CAR-M THERAPY TO BE PRESENTED ON NOVEMBER 8 AT SITC 2024 ANNUAL MEETING NEW PRECLINICAL EFFICACY DATA IN LIVER FIBROSIS TO BE PRESENTED ON NOVEMBER 17 AT AASLD - THE LIVER MEETING  2024 CASH AND CASH EQUIVALENTS OF $26.9 MILLION EXPECTED TO FUND THE COMPANY INTO THE THIRD QUARTER OF 2025 PHILADELPHIA , NOV. 7, 2024 /PRNEWSWIRE/ -- CARISMA THERAPEUTICS INC.(NASDAQ: CARM) ("CARISMA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING INNOVATIVE IMMUNOTHERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2024, AND HIGHLIGHTED RECENT BUSINESS UPDATES. "OUR RECENT PROGRESS ACROSS CLINICAL AND PRECLINICAL PROGRAMS DEMONSTRATES OUR COMMITMENT TO PIONEERING THERAPIES THAT ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS," SAID STEVEN KELLY, PRESIDENT AND CEO OF CARISMA THERAPEUTICS.

Carisma Therapeutics, Inc.

CARM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Carisma Therapeutics, Inc.

CARM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CARM